A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Conditions: Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarian Cancer; BRCA2 Mutation; ER+ Breast Cancer; Castrate Resistant Prostate Cancer; BRCA1 Mutation; BRCA Mutation; Endometrial Cancer; Colorectal Cancer; Gastric Cancer Interventions: Drug: ETX-19477 Sponsors: 858 Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials